Mitochondrial microRNAs Are Dysregulated in Patients with Fabry Disease
暂无分享,去创建一个
D. Sorriento | Guido Iaccarino | E. Riccio | A. Pisani | G. Santulli | J. Gambardella | A. Fiordelisi | F. Cerasuolo | Fahimeh Varzideh | Antonietta Buonaiuto | Roberta Avvisato | F. Varzideh
[1] G. Santulli,et al. Functional Role of microRNAs in Regulating Cardiomyocyte Death , 2022, Cells.
[2] C. Maack,et al. Mitochondria as Therapeutic Targets in Heart Failure , 2022, Current Heart Failure Reports.
[3] G. Santulli,et al. Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[4] M. Ferracin,et al. Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease , 2021, Cell Death & Disease.
[5] M. Brandi,et al. MicroRNAs as Potential Biomarkers in Pituitary Adenomas , 2021, Non-coding RNA.
[6] A. Coppola,et al. Role of endothelial miR-24 in COVID-19 cerebrovascular events , 2021, Critical Care.
[7] J. Wojta,et al. MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease , 2021, Genes.
[8] M. Lenassi,et al. Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy , 2021, Genes.
[9] V. Parra,et al. Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF. , 2021, Biochimica et biophysica acta. Molecular basis of disease.
[10] Xinxing Wang,et al. Regulation of Mitochondrial Function by Noncoding RNAs in Heart Failure and Its Application in Diagnosis and Treatment , 2021, Journal of cardiovascular pharmacology.
[11] A. Lymperopoulos,et al. Impact of Aldosterone on the Failing Myocardium: Insights from Mitochondria and Adrenergic Receptors Signaling and Function , 2021, Cells.
[12] Xiang-chun Shen,et al. MicroRNAs Regulating Mitochondrial Function in Cardiac Diseases , 2021, Frontiers in Pharmacology.
[13] P. Pinton,et al. Mitochondrial Bioenergetics and Dynamism in the Failing Heart , 2021, Life.
[14] G. Santulli,et al. miR-24 Targets the Transmembrane Glycoprotein Neuropilin-1 in Human Brain Microvascular Endothelial Cells , 2021, Non-coding RNA.
[15] J. Blusztajn,et al. MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease , 2021, Non-coding RNA.
[16] D. Sorriento,et al. The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field , 2021, International journal of molecular sciences.
[17] N. Sousa,et al. Fabry Disease Therapy: State-of-the-Art and Current Challenges , 2020, International journal of molecular sciences.
[18] P. Graziano,et al. Non-Coding RNAs as Prognostic Biomarkers: A miRNA Signature Specific for Aggressive Early-Stage Lung Adenocarcinomas , 2020, Non-coding RNA.
[19] A. Tuttolomondo,et al. Biomarkers in Anderson–Fabry Disease , 2020, International journal of molecular sciences.
[20] D. Sorriento,et al. Role of Endothelial G Protein-Coupled Receptor Kinase 2 in Angioedema , 2020, Hypertension.
[21] S. Feriozzi,et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data , 2020, European Journal of Human Genetics.
[22] F. Weidemann,et al. Diagnosis and Screening of Patients with Fabry Disease , 2020, Therapeutics and clinical risk management.
[23] N. Dahms,et al. Progress in the understanding and treatment of Fabry disease. , 2020, Biochimica et biophysica acta. General subjects.
[24] Lubo Zhang,et al. Mitochondrial MiRNA in Cardiovascular Function and Disease , 2019, Cells.
[25] P. Nordbeck,et al. Circulating microRNAs in Fabry Disease , 2019, Scientific Reports.
[26] R. Schiffmann,et al. Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey , 2019, Advances in Therapy.
[27] S. Booth,et al. MicroRNAs in Neuroinflammation: Implications in Disease Pathogenesis, Biomarker Discovery and Therapeutic Applications , 2019, Non-coding RNA.
[28] A. Kriegel,et al. miR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells. , 2019, American journal of physiology. Heart and circulatory physiology.
[29] E. Riccio,et al. A pilot study of circulating microRNAs as potential biomarkers of Fabry disease , 2018, Oncotarget.
[30] A. Andrade,et al. Influence of exercise on oxidative stress in patients with heart failure , 2018, Heart Failure Reviews.
[31] S. Feriozzi,et al. Contribution of inflammatory pathways to Fabry disease pathogenesis. , 2017, Molecular genetics and metabolism.
[32] Xiaoxia Wang,et al. Mitochondria Associated MicroRNA Expression Profiling of Heart Failure , 2017, BioMed research international.
[33] C. Melon,et al. Inhibition of the Mitochondrial Glutamate Carrier SLC25A22 in Astrocytes Leads to Intracellular Glutamate Accumulation , 2017, Front. Cell. Neurosci..
[34] Lang Li,et al. MiR-486 regulates cardiomyocyte apoptosis by p53-mediated BCL-2 associated mitochondrial apoptotic pathway , 2017, BMC Cardiovascular Disorders.
[35] G. Tiscornia,et al. Mitochondrial Dysfunction in Lysosomal Storage Disorders , 2016, Diseases.
[36] D. Lockhart,et al. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.
[37] A. Longo,et al. Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2 , 2016, Amino Acids.
[38] Gaetano Santulli,et al. Mitochondrial calcium overload is a key determinant in heart failure , 2015, Proceedings of the National Academy of Sciences.
[39] Sabine C. Mueller,et al. miRNAs can be generally associated with human pathologies as exemplified for miR-144* , 2014, BMC Medicine.
[40] G. Paolisso,et al. Functional role of miRNA in cardiac resynchronization therapy. , 2014, Pharmacogenomics.
[41] Yi Zhang,et al. MicroRNA Directly Enhances Mitochondrial Translation during Muscle Differentiation , 2014, Cell.
[42] G. Condorelli,et al. Atrial fibrillation and microRNAs , 2014, Front. Physiol..
[43] M. Kimura,et al. MiR-184 regulates insulin secretion through repression of Slc25a22 , 2013, PeerJ.
[44] J. Oliveira,et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications , 2013, Orphanet Journal of Rare Diseases.
[45] G. Burton,et al. Suppression of Mitochondrial Electron Transport Chain Function in the Hypoxic Human Placenta: A Role for miRNA-210 and Protein Synthesis Inhibition , 2013, PloS one.
[46] M. Sabbatini,et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. , 2012, Molecular genetics and metabolism.
[47] Sarah J. Wheelan,et al. Nuclear miRNA Regulates the Mitochondrial Genome in the Heart , 2012, Circulation research.
[48] M. Latronico,et al. The might of microRNA in mitochondria. , 2012, Circulation Research.
[49] P. Brugada,et al. Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease , 2012, PloS one.
[50] B. Prabhakar,et al. Control of mitochondrial activity by miRNAs , 2012, Journal of cellular biochemistry.
[51] M. Ciccarelli,et al. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. , 2011, The American journal of cardiology.
[52] Jiayou Zhang,et al. miR-17* Suppresses Tumorigenicity of Prostate Cancer by Inhibiting Mitochondrial Antioxidant Enzymes , 2010, PloS one.
[53] G. Shulman,et al. Regulation of mitochondrial biogenesis. , 2010, Essays in biochemistry.
[54] Y. Naito,et al. The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity. , 2010, American journal of physiology. Endocrinology and metabolism.
[55] C. Steer,et al. MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis , 2009, RNA biology.
[56] A. Aschrafi,et al. MicroRNA-338 Regulates Local Cytochrome c Oxidase IV mRNA Levels and Oxidative Phosphorylation in the Axons of Sympathetic Neurons , 2008, The Journal of Neuroscience.
[57] A. Das,et al. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. , 2004, Molecular genetics and metabolism.
[58] B. Schermer,et al. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. , 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.
[59] Quincy A. Hathaway,et al. Role of microRNA in metabolic shift during heart failure. , 2017, American journal of physiology. Heart and circulatory physiology.
[60] G. Santulli,et al. Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. , 2015, Advances in experimental medicine and biology.
[61] G. Santulli,et al. MicroRNA: From Molecular Biology to Clinical Practice , 2015 .
[62] G. Santulli. Exploiting microRNA Specificity and Selectivity: Paving a Sustainable Path Towards Precision Medicine. , 2015, Advances in experimental medicine and biology.
[63] P. Luna,et al. [Fabry disease]. , 2009, Anais brasileiros de dermatologia.
[64] H. Naim,et al. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. , 2009, Advances in clinical chemistry.
[65] R. Desnick,et al. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. , 2001, American journal of human genetics.
[66] J. Schmidt. Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. , 1990, Biomedica biochimica acta.